Merck Vytorin Early Positive Review

Merck Vytorin Early Positive Review – A recent find which claims that the drug Vytorin reduces the risk of heart attacks and stroke is good news for the pharmaceutical company Merck & Co. The study which produced these results involved 9,000 people who had chronic kidney disease which was in its final stage.

The findings of this study were presented at the American Society of Nephrology meeting which took place in Denver. The drug managed to reduce the risk of heart attack or stroke in these patients by around 16 percent, a huge triumph for the drug company that was hoping for positive results which they most certainly got.

Merck is a drug company that is based out of Whitehouse Station in New Jersey; it said that the study which was recently done is very pertinent to the effectiveness of the drug because those who have kidney disease are especially at risk for vascular problems.

Because Merck has been dealing with a lot of competition from all ends in the pharmaceutical market, they have expressed their happiness with the results of the study which suggest that the medication can really do great things for those who take it to prevent problems like heart attacks and stroke as a result of kidney problems or some other health issue.

Leave a Comment